Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATI-5923 for Anticoagulation in Atrial Fibrillation
NCT00431782Phase 2Completed
- Sponsor
- ARYx Therapeutics
- Start
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tecarfarin in Atrial fibrillation (AFib), sponsored by ARYx Therapeutics. Primary endpoints: International Normalized Ratio, Coagulation Factors II, VII, IX and X and 1 more. Started Dec 2006; status: completed.
02
Drugs
tecarfarin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT00431782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00431782.